You are here
As part of the Opioid Initiative, NIH is working with FDA and private sector experts to draft a plan for a formal partnership to advance specific pharmacological treatments for pain and addiction. In 2017, NIH convened a series of meetings with experts from across government, industry and academia to determine the pharmacological areas that could be best addressed through a public-private partnership. Two high priority goals emerged:
Short Term: Enhance the range of medication options to treat opioid use disorders, prevent and reverse overdoses, and support long term recovery in patients
- Develop new formulations and combinations of existing medications to treat opioid use disorder, and to prevent and/or reverse overdose;
- Identify potential new uses for existing or abandoned medications that may be useful in treating addiction, overdose, or pain;
Longer Term: Develop new alternatives for pain relief, including safe, more effective, and non-addictive pain relievers or non-opioid analgesics
- Facilitate sharing data to focus future resources and research and spur innovation in developing new pain medications;
- Establish new clinical trial networks with innovative study design to accelerate drug development for patients with high unmet needs for treatment;
- Develop methods to objectively measure pain in patients, and to identify biomarkers for more rapid discovery, development and approval of new medications.
NIH will support additional research to facilitate and augment these goals.
This page last reviewed on December 11, 2017